Citations

Mayo Clinic

Clear

1899 citation(s) found for "Núñez, Sara".

Metabolic hallmarks of trastuzumab resistance
Llop‐Hernández, Àngela , Lupu, Ruth , Martı́n-Castillo, Begoña , Verdura, Sara , Cuyàs, Elisabet , Menéndez, Javier A.

Expert Opinion on Therapeutic Targets | July 11, 2025 | Volume: 29 | Issue: 7 | Pages: 457-479

10.1080/14728222.2025.2532394 | PMID 40642957 Get It

Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population
Prinzi, Federica Lo , Salani, Francesca , Saborowski, Anna , Antonuzzo, Lorenzo , Rossari, Federico , Satake, Tomoyuki, Peeters, Frederik , Pressiani, Tiziana , Kim, Jin Won , Finkelmeier, Fabian , Chiara, Pircher, Chon, Hong Jae , Braconi, Chiara , Qaisar, Aitzaz, Pastorino, Alessandro , Castet, Florian , Parisi, Alessandro , Perkhofer, Lukas , Adeva, Jorge , Spinelli, Gian Paolo , Rodriquenz, Maria Grazia , Leo, Silvana, Alvim, Cecilia Melo, Polito, M.G. , Giacomo, Emanuela Di , Bartalini, L. , Grelli, Giada, Rosa, Antonio De, Lavacchi, Daniele, Ikeda, Masafumi, Dekervel, Jeroen , Balsano, Rita , Tesini, Giulia , Boccaccino, Alessandra , Himmelsbach, Vera, Vogel, Arndt, Rimassa, Lorenza , Casadei‐Gardini, Andrea, Vogel, Arndt , Casadei‐Gardini, Andrea , Rossari, Federico , Prager, Gerald W , Farinea, Giovanni , Niger, Monica , Rimini, Margherita , Antonuzzo, Lorenzo , Lo Prinzi, Federica , Parisi, Alessandro , Casadei-Gardini, Andrea , Finkelmeier, Fabian , Castet, Florian , Adeva, Jorge , Tesini, Giulia , Rimassa, Lorenza , Casadei-Gardini, Andrea , Saborowski, Anna , Pressiani, Tiziana , Jae Chon, Hong , Salani, Francesca , De Rosa, Antonio , Dekervel, Jeroen , Vogel, Arndt , Camera, Silvia , Lucchetti, Jessica , Abidoye, Oluseyi , Rapposelli, Ilario Giovanni , Gallio, Chiara , Tamberi, Stefano , Giordano, Guido , Chiara, Pircher, Tamburini, Emiliano , Yoo, Changhoon , Diana, Anna , Scartozzi, Mario , Prager, Gerald W. , Avallone, Antonio , Schirripa, Marta , Kim, Il Hwan , Oneda, Ester , Verrico, Monica , Couto, Nuno , Chan, Stephen L. , Personeni, Nicola , Garajova, Ingrid , Roque, Ricardo , Ikeda, Masafumi , Niger, Monica , Tonini, Giuseppe , Kang, Minsu , Landriscina, Matteo , Djaballah, Selma Ahcene , Bekaii‐Saab, Tanios , Fornaro, Lorenzo , Masi, Gianluca , Lonardi, Sara , Rimini, Margherita

International Journal of Cancer | July 11, 2025 | Volume: 157 | Issue: 10 | Pages: 2092-2102

10.1002/ijc.70009 | PMID 40641448 Get It

Abstract In recent years, there has been increasing interest in the possible prognostic impact of concomitant medications in patients with cancer treated with immunotherapy combinations. This real‐world analysis aims to evaluate the impact of concomitant medications on survival outcomes in patients with advanced biliary tract cancer (BTCs) treated with cisplatin, gemcitabine and durvalumab (CGD) therapy. The study cohort included patients with a diagnosis of advanced BTCs who were taking concomitant medications for their comorbidities before the start of CGD. The primary objectives were overall survival (OS) and progression‐free survival (PFS). The initial population consisted of 666 patients, who were retrospectively collected from 41 sites in 12 countries. Data on concomitant medications were available for 493 patients. After a median follow‐up of 8.8 months (95% CI: 7.8–9.8), patients who did not take steroids (prednisone >10 mg/day or equivalent) or nonsteroidal anti‐inflammatory drugs (NSAIDs) and opioids, before the start of CGD, had longer OS and PFS in univariate analysis. The multivariate analysis confirmed longer OS for patients who did not take steroids. Patients who did not take steroids had an OS of 14.8 months (95% CI: 13.1–29.1) versus 5.0 months (95% CI: 2.14–11.32) of patients who took prednisone >10 mg/day or equivalent. No differences were reported in terms of overall response rate (ORR), disease control rate (DCR) ( p = 1.0 and p = .16, respectively), and safety profile between the two groups. Our analysis suggests that patients who did not receive steroids before the start of GCD had longer survival and highlighted the relevance of balancing concomitant medications and chemoimmunotherapy.
Facial Anatomy Teaching for Aesthetic Surgery: Using 3-dimensional Photogrammetry and Immersive Virtual Reality
Hussein, Sara , Emanuels, Andrew F., Leonel, Luciano, Lachman, Nirusha , Celda, María Peris, Sheahan, Eric M., Martinez, Erick O., Leonel, Luciano César P C, Peris Celda, Maria, Hanson, Christian R., Emanuels, Andrew, Morris, Jonathan M. , Martinez, Erick O., Hanson, Christian R., Sharaf, Basel

Plastic and Reconstructive Surgery - Global Open | July 9, 2025 | Volume: 13 | Issue: 7 | Pages: e6972

10.1097/gox.0000000000006972 | PMID 40642258 Get It

Summary: Anatomy is a critical component of surgical training; however, traditional resources—such as Netter’s Surgical Anatomy , Gray’s Anatomy , and anatomy applications—often fall short in delivering surgically relevant, 3-dimensional (3D) perspectives of facial anatomy. Although cadaveric dissection remains a valuable teaching tool, its accessibility is limited by cost, ethical concerns, and the lack of structured curricula, making it less feasible for ongoing surgical education. To address these limitations, this article introduced a novel educational approach that integrates 3D photogrammetry and virtual reality technology into the surgical anatomy curriculum for craniofacial and aesthetic surgery. Six fresh cadaveric specimens were meticulously dissected by a plastic surgeon to illustrate the intricate layered anatomy of the face and neck. At each stage of the dissection, a photogrammetry technique was used to capture 360-degree images using 5 digital single-lens reflex cameras alongside a 3D handheld camera. This approach not only ensured high-quality imaging but also facilitated the creation of detailed, lifelike virtual 3D models, enhancing the understanding of facial and neck anatomy within a surgical context. Additionally, we present some technical refinements of the 3D volume renderings to capture precise anatomical details during our dissections. Preliminary results from the use of this technology in anatomy courses and workshops indicated trainee engagement, a clearer grasp of the spatial anatomical relationships, and greater confidence in applying this knowledge to hands-on surgical procedures.
AncestryGeni: a novel genetic ancestry classification pipeline for small and noisy sequence data
Elhaik, Eran , Behnamian, Sara , Howe, M. S., Tang, Hongwei , Yan, Huihuang , Tian, Shulan , Shivaram, Suganti, Mendoza, Cinthya Zepeda, Blaney, Patrick , Howe, Michael, Zepeda Mendoza, Cinthya, Maura, Francesco , Baughn, Linda B , Elhaik, Eran , Tian, Shulan , Blaney, Patrick , Howe, Michael, Zepeda‐Mendoza, Cinthya , Maclachlan, Kylee , Usmani, Saad Z. , Pirooznia, Mehdi , Morgan, Gareth J. , Maura, Francesco , Baughn, Linda B.

Bioinformatics | July 8, 2025 | Volume: 41 | Issue: 7 | Pages: No page available

10.1093/bioinformatics/btaf391 | PMID 40627371 Get It

Abstract Motivation Efforts to address health disparities are often limited by the lack of robust computational tools for inferring genetic ancestry by calculating an individual’s genetic similarity to continental groups. We have already shown that a preferred alternative to self-described race is using ancestry-informative markers (AIMs) that can be classified into ancestral components and used to estimate their similarity to those of known populations to identify continental groups. However, real-world genomic data can present challenges, including limited availability of germline DNA, a small number of AIMs for each sample, and the use of different variant calling software, limiting the application of existing solutions. Results Here, we describe a novel supervised machine-learning tool AncestryGeni, which infers genetic ancestry for samples with even a hundred markers and is applicable to any genomic data, including whole exome sequencing (WES) and RNA sequencing (RNA-Seq) data. Applying AncestryGeni to a real-world genomic dataset obtained from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study, we show that it is more accurate than the commonly used FastNGSadmix when using nonstandard genomic material. We also demonstrate that when using AncestryGeni, the tumor-derived sequence obtained from WES and RNA-Seq can be a robust data source to accurately estimate an individual’s genetic similarity to a continental group. Availability and implementation AncestryGeni pipeline is available at https://github.com/eelhaik/AncestryGeni/tree/main.
Invasive and Non-Invasive Neuromodulation for the Treatment of Substance Use Disorders: A Review of Reviews
Oesterle, Tyler , Bormann, Nicholas L. , Al‐Soleiti, Majd , Kung, Simon , Singh, Balwinder , McGinnis, Michele , Costa, Sabrina Corrêa da , Rummans, Teresa A. , Chauhan, Mohit , Cabrera, Juan M. Rojas , Vettleson-Trutza, Sara A. , Scheitler, Kristen M. , Shin, Hojin , Lee, Kendall H. , Gold, Mark S. , Oesterle, Tyler S , McGinnis, Michele T , Correa da Costa, Sabrina, Rummans, Teresa , Rojas Cabrera, Juan M , Singh, Balwinder , Vettleson-Trutza, Sara , Bormann, Nicholas L , Chauhan, Mohit

Brain Sciences | July 7, 2025 | Volume: 15 | Issue: 7 | Pages: 723

10.3390/brainsci15070723 | PMID 40722314 Get It

Background: Invasive and non-invasive neuromodulation in psychiatry represents a burgeoning field that leverages advanced neuromodulation techniques to address substance use disorders (SUDs). Aims: This narrative review synthesizes findings from multiple reviews to evaluate the efficacy of neuromodulation in treating SUDs. Methods: A comprehensive literature search was conducted between December 2024 and April 2025, focusing on systematic reviews and meta-analyses that examined various neuromodulation modalities, including repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and deep brain stimulation (DBS). The selected reviews were analyzed to identify common themes, outcomes, and gaps in the current understanding of these treatments for SUDs. Results: 11 reviews met the final inclusion criteria; 5 focused on non-invasive neuromodulation (rTMS, tDCS) and 6 on invasive neuromodulation (DBS). Non-invasive neurostimulation was associated with modest improvements in craving and cognitive dysfunction in individuals with SUDs. Similarly, invasive neuromodulation (DBS), through high-frequency stimulation of the bilateral nucleus accumbens, appeared to reduce cravings and improve comorbid psychiatric symptoms in both preclinical and human studies. Importantly, small sample sizes, heterogeneity in targets and stimulation protocols, and short follow-up periods significantly limit the generalizability of current findings from both non-invasive and invasive neuromodulation studies. Conclusions: As novel and more effective therapies for the treatment of SUD are desperately needed, procedural interventional psychiatry holds promise. However, despite encouraging results, existing evidence is still preliminary, and larger, rigorously designed studies are warranted to further establish the safety and efficacy of neuromodulatory interventions for SUD treatment.
Interobserver reproducibility of hilar soft tissue invasion in testicular germ cell tumours among genitourinary pathologists
Wu, Douglas, Williamson, Sean R. , Pacheco, Richard R. , Acosta, Andrés , Al‐Obaidy, Khaleel I. , Amin, Mahul B. , Berney, Daniel M. , Brimo, Fadi , Cheng, Liang , Cornejo, Kristine M. , Downes, Michelle R. , Epstein, Jonathan I. , Hirsch, Michelle S. , Jiménez, Rafael E. , Kaushal, Seema , Lobo, Anandi , Mehra, Rohit , Mohanty, Sambit K. , Paner, Gladell P. , Reuter, Victor E. , Smith, Steven C. , Tretiakova, Maria , Trpkov, Kiril , Wobker, Sara E. , Tamboli, Pheroze, Zynger, Debra L. , Sangoi, Ankur R , Cheng, Liang , Sangoi, Ankur R. , Williamson, Sean R , Acosta, Andrés M , Al-Obaidy, Khaleel , Berney, Daniel M , Comperat, Eva , Downes, Michelle , Hirsch, Michelle S , Jimenez, Raphael E , Mehra, Rohit , Mohanty, Sambit K , Smith, Steven , Tretiakova, Maria S , Trpkov, Kiril , Zynger, Debra , Sangoi, Ankur R , Cheng, Liang , Sangoi, Ankur R , Akgül, Mahmut , Colecchia, Maurizio , Compérat, Éva , Dhillon, Jasreman , López-Beltrán, Antonio , Rao, Priya , Shah, Rajal B. , Shen, Steven S. , Tamboli, Pheroze

Histopathology | July 4, 2025 | Volume: 87 | Issue: 5 | Pages: 677-686

10.1111/his.15504 | PMID 40611804 Get It

AimsCompared to lymphovascular invasion (LVI), hilar soft tissue invasion (HSTI) is a relatively novel pT2 staging parameter in testicular germ cell tumours (GCT), associated with metastasis at the time of diagnosis and a risk factor for disease relapse. Given diagnostic variability in how pathologists interpret HSTI, herein we explore interobserver reproducibility among genitourinary (GU) pathologists.MethodsTwenty haematoxylin and eosin‐stained digitized slides from testicular GCTs were distributed to 30 GU pathologists to classify each as HSTI or not HSTI based on their respective clinical practices; slides with concomitant LVI were excluded. Slides were then evaluated for the following morphologic features: tumour invasion beyond prominent hilar vessels, tumour invasion beyond the rete, tumour invasion beyond the level parallel to hilar adipose tissue and tumour within (directly touching) hilar adipose tissue. Interobserver reproducibility was assessed, and the morphological features were correlated with HSTI. Relationships between pathologists' interpretations, morphological features and HSTI were evaluated using hierarchical clustering.ResultsAlthough the diagnosis of HSTI was relatively uniform with a majority agreement (>67%) reached in 17/20 slides, overall interobserver reproducibility was only moderate (kappa = 0.50). Morphological features such as invasion beyond the level parallel to hilar adipose tissue and invasion into fat were more sensitive and specific for HSTI, while features such as invasion beyond hilar vessels and invasion beyond rete were less useful.ConclusionsThese findings suggest that more specific defined diagnostic criteria for testicular GCT HSTI are needed.
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population
Prinzi, Federica Lo , Rizzato, Mario Domenico , Saborowski, Anna , Antonuzzo, Lorenzo , Rossari, Federico , Satake, Tomoyuki, Peeters, Frederik , Pressiani, Tiziana , Finkelmeier, Fabian , Braconi, Chiara , Qaisar, Aitzaz, Pirrone, Chiara, Castet, Florian , Parisi, Alessandro , Scartozzi, Mario, Corallo, Salvatore , Perkhofer, Lukas , Adeva, Jorge , Spinelli, Gian Paolo , Rodriquenz, Maria Grazia , Leo, Silvana, Alvim, Cecilia Melo, Roque, Ricardo , Salani, Francesca , Rosa, Antonio De, Lavacchi, Daniele, Dekervel, Jeroen , Niger, Monica, Balsano, Rita , Esposito, Luca, Boccaccino, Alessandra , Himmelsbach, Vera, Zanuso, Valentina , Vogel, Arndt, Rimassa, Lorenza , Casadei‐Gardini, Andrea , Vogel, Arndt , Lo Prinzi, Federica , Rizzato, Mario Domenico , Saborowski, Anna , Antonuzzo, Lorenzo , Rossari, Federico , Peeters, Frederik , Pressiani, Tiziana , Lucchetti, Jessica , Kim, Jin Won , Abidoye, Oluseyi , Rapposelli, Ilario Giovanni , Finkelmeier, Fabian , Giordano, Guido , Nichetti, Federico , Jae Chon, Hong , Qaisar, Aitzaz , Pirrone, Chiara , Castet, Florian , Tamburini, Emiliano , Parisi, Alessandro , Scartozzi, Mario , Avallone, Antonio , Corallo, Salvatore , Schirripa, Marta , Oneda, Ester , Verrico, Monica , Adeva, Jorge , Chan, Stephen L , Spinelli, Gian Paolo , Personeni, Nicola , Garajova, Ingrid , Rodriquenz, Maria Grazia , Roque, Ricardo , Farinea, Giovanni , Salani, Francesca , De Rosa, Antonio , Camera, Silvia , Ikeda, Masafumi , Dekervel, Jeroen , Niger, Monica , Kang, Minsu , Bekaii-Saab, Tanios S , Esposito, Luca , Boccaccino, Alessandra , Djaballah, Selma Ahcene , Zanuso, Valentina , Masi, Gianluca , Vogel, Arndt , Lonardi, Sara , Rimassa, Lorenza , Casadei-Gardini, Andrea , Casadei-Gardini, Andrea , Rimini, Margherita , Fornaro, Lorenzo , Vivaldi, Caterina , Kim, Jin Won , Abidoye, Oluseyi , Tamberi, Stefano , Nichetti, Federico , Chon, Hong Jae , Yoo, Changhoon , Diana, Anna , Prager, Gerald W. , Kim, Il Hwan , Chan, Stephen L. , Ikeda, Masafumi , Niger, Monica , Tonini, Giuseppe , Bekaii‐Saab, Tanios , Landriscina, Matteo , Malapelle, Umberto , Pepe, Francesco , Lonardi, Sara

JNCI: Journal of the National Cancer Institute | July 3, 2025 | Volume: 117 | Issue: 10 | Pages: 2029-2043

10.1093/jnci/djaf155 | PMID 40608977 Get It

Abstract Background Cisplatin, gemcitabine, and durvalumab combination is a standard first-line treatment for advanced biliary tract cancer. This study aimed to assess the impact of genetic alterations on outcomes in patients with advanced biliary tract cancer treated with cisplatin, gemcitabine, and durvalumab in real-world clinical practice. Methods Patients with unresectable, locally advanced, or metastatic biliary tract cancer treated with cisplatin and gemcitabine plus durvalumab across 39 centers in 11 countries in Europe, the United States, and Asia were included in this analysis. Results The cohort included 513 patients with advanced biliary tract cancer. The 5 most frequently altered genes were TP53 (22.1%), KRAS (13.7%), CDKN2A/B (13.6%), ARID1A (12.2%), and IDH1 (9.2%). In multivariate analysis, SMAD4 mutations were associated with improved progression-free survival (PFS) (hazard ratio [HR] = 0.49, P = .018) and overall survival (HR = 0.11, P = .023), while TP53 mutations were linked to worse PFS (HR = 1.62, P = .0047) and TERT mutations to worse overall survival (HR = 8.92, P = .0012). No other genomic alterations were statistically associated with outcomes. Subgroup analysis showed that TP53 mutations negatively affected PFS and overall survival in intrahepatic cholangiocarcinoma, while KRAS mutations were associated with poorer PFS in extrahepatic cholangiocarcinoma. No gene alterations were linked to outcomes in gallbladder cancer. Conclusions This large-scale analysis, with comprehensive molecular profiling, supports the positive prognostic impact of SMAD4 mutations for PFS and overall survival and highlights the negative prognostic roles of TP53 (PFS) and TERT (overall survival) mutations, providing valuable insights for personalized treatment strategies in biliary tract cancer.
Promoting retention through belonging: A path to gender equity in oncologic specialties
Katz, Nicole B. , Lee, Yeonsoo Sara , Chin, Eliza Lo, Sara Lee, Yeonsoo

Cancer | July 3, 2025 | Volume: 131 | Issue: 13 | Pages: No page available

10.1002/cncr.35952 | PMID 40607650 Get It

Epilepsy Care in the Real World of Multiple Medical Considerations
Klocke, Shilpa , Eyal, Sara , Dubey, Divyanshu , Alick-Lindstrom, Sasha , Das, Rohit , Eyal, Sara , Alick-Lindstrom, Sasha , Das, Rohit R , Dubey, Divyanshu , Stern, John M. , Lekoubou, Alain

Epilepsy Currents | July 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15357597251320144 | PMID 40621489 Get It

Similar to the general population, people with epilepsy (PWE) will often have multiple medical issues that may impact their care. It is therefore important for epilepsy clinicians to be aware of these issues to optimize treatment and quality of life outcomes. In this review, we discuss cardiovascular and respiratory as well as infectious disorders in PWE. We also examine autoimmune disorders and outline reproductive and sexual health issues.
Condylomatous Sinonasal Papilloma—A Distinct (Fourth) Subtype That is Commonly Associated With Low-risk Human Papillomavirus
Mehreen, Ansa , Mehrad, Mitra , Ely, Kim, Kuo, Ying‐Ju , Velez-Torres, Jaylou M., Penner, Carla, Amin, Sara E. , Saluja, Karan , Lewis, James S. , Lewis, James S , Hang, Jen‐Fan , Chernock, Rebecca

American Journal of Surgical Pathology | July 3, 2025 | Volume: 49 | Issue: 9 | Pages: 873-881

10.1097/pas.0000000000002431 | PMID 40605275 Get It

Inverted papilloma (IP) is a benign neoplasm of the nasal cavity and paranasal sinuses, known for its variable risk of recurrence and potential for developing carcinoma. Emerging evidence has shown high rates of activating EGFR mutation, and a smaller subset is associated with low-risk human papillomavirus (lrHPV). While certain morphologic features, including an inverted growth pattern, are well-established, the presence of condylomatous features, such as large fungating lesions with thick undulating surface epithelium, hyperkeratosis, cytoplasmic clearing, raisinoid nuclei, and binucleation (koilocytic changes) in low-risk HPV-associated IP suggests that these tumors may be a distinct subtype of sinonasal papilloma (SP) with features similar to low-risk HPV-associated anogenital condylomas. This study presents a series of SP with condylomatous morphology and explores the association with lrHPV, the clinicopathologic features, and the rates of carcinoma development. In total, 17 cases of SP exhibiting condylomatous morphology were retrospectively identified. We performed lrHPV and high-risk HPV (hrHPV) RNA in situ hybridization and p16 immunohistochemistry and gathered detailed clinical and pathologic data along with treatment, disease follow-up, and outcomes. These condylomatous papillomas almost all developed in active smokers, were large, were primarily located in the nasal cavity (47%), and showed frequent transformation to invasive squamous cell carcinoma (29%). This malignant transformation rate is much higher than what has been reported for inverted, exophytic, and oncocytic papillomas. The tumors were almost uniformly associated with transcriptionally-active lrHPV (94%) and were consistently negative for p16 and hrHPV. This study shows that a subgroup of IPs with condylomatous morphology have a predilection for the nasal cavity, strong association with lrHPV, and high rates of carcinoma. These findings support the concept that these tumors are a distinct (fourth) type of SP with a higher risk of malignant transformation.